seekingalpha.com
/4 weeks ago
Latest updates for Sndx
Fresh curated links around SNDX are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- Syndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call Transcript
- Kura Oncology: Commercialization In AML Presents Asymmetric Upside
- Ascendis Pharma A/S (ASND) Reports Positive Week 52 Data from Phase 2 New InsiGHTS Trial
Post angles to try
Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
seekingalpha.com
/1 month ago
Kura Oncology: Commercialization In AML Presents Asymmetric Upside
finance.yahoo.com
/1 month ago
Ascendis Pharma A/S (ASND) Reports Positive Week 52 Data from Phase 2 New InsiGHTS Trial
newswire.com
/1 month ago
NX Development Corp Submits Supplemental New Drug Application to FDA for MEN-301 Study
NX Development Corp (NXDC) submits an sNDA to the FDA for Gleolan based on the MEN-301 study to improve visualization during meningioma surgery. Learn more.
seekingalpha.com
/3 weeks ago
Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript
seekingalpha.com
/7 hours ago
Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win
seekingalpha.com
/1 month ago
TD SYNNEX Corporation 2026 Q1 - Results - Earnings Call Presentation
seekingalpha.com
/1 month ago
Nektar Therapeutics: 'Strong Buy' On REZPEG POC Established In AD/AA And Late-Stage Development
cafepharma.com
/3 weeks ago
Sang
Sang Anonymous (not verified) Thu, 05/07/2026 - 02:21 field_thread_url https://cafepharma.com/boards/threads/sang.673523/ board name...
seekingalpha.com
/1 month ago
Senzime AB (publ) (SNZZF) Q1 2026 Earnings Call Transcript
fool.com
/3 weeks ago
Ascendis (ASND) Q1 2026 Earnings Call Transcript
Image source: The Motley Fool. DATEThursday, May 7, 2026 at 8 a.m. ETCALL PARTICIPANTSPresident and Chief Executive Officer — Jan MikkelsenChief Financial Officer — Scott SmithChi...
seekingalpha.com
/1 month ago
Recursion Pharmaceuticals May Be Losing Ground To Its Peers
cafepharma.com
/1 month ago
Axonics
Axonics Anonymous (not verified) Sun, 04/05/2026 - 17:00 field_thread_url https://cafepharma.com/boards/threads/axonics.704805/ board na...
seekingalpha.com
/1 month ago
Senzime AB (publ) 2026 Q1 - Results - Earnings Call Presentation
seekingalpha.com
/1 month ago
Senzime AB (publ) 2026 Q1 - Results - Earnings Call Presentation
fool.com
/1 week ago
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions.
seekingalpha.com
/1 month ago
Nexity SA (NNXXY) Q1 2026 Sales/ Trading Statement Call - Slideshow
cafepharma.com
/3 weeks ago
Axonics
Axonics Anonymous (not verified) Sat, 05/09/2026 - 08:22 field_thread_url https://cafepharma.com/boards/threads/axonics.704805/ board na...
finance.yahoo.com
/1 month ago
Barrington Raises its Price Target on TD SYNNEX (SNX) to $202
seekingalpha.com
/1 month ago
Allogene: Early ALPHA3 Data Suggests Potential Paradigm Shift For Cema-Cel In LBCL
pharmexec.com
/1 month ago
<![CDATA[Neurocrine Enters $2.9 Billion Agreement to Acquire Soleno Therapeutics ]]>
finance.yahoo.com
/2 weeks ago
CDT Equity Advances AstraZeneca PLC (AZN)’s AZD5904 Into PCT Patent Protection Stage
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.
Sources covering Sndx
seekingalpha.com
Recent coverage from public sources
Public source
cafepharma.com
Recent coverage from public sources
Public source
finance.yahoo.com
Recent coverage from public sources
Public source
seekingalpha.com
Recent coverage from public sources
Public source
fool.com
Recent coverage from public sources
Public source
newswire.com
Recent coverage from public sources
Public source